The effort will apply Arcxis’s proprietary technology for isolation and concentration of total RNA and genomic DNA to PCR and RT-PCR based diagnostic tests.
Arcxis believes that its rapid and sensitive methods for preparing blood and tissue will translate into significant performance benefits.
Christine Meda, president and CEO of Arcxis, said: “We are very pleased to enter into this collaboration with Roche. Partnering with a global diagnostic provider offers a unique opportunity for Arcxis to apply its technologies to the detection of infectious diseases and cancer.”